智翔金泰：公司GR2001注射液新药上市申请已于2025年5月获受理，目前处于排队待审评状态

Group 1 - The core point of the article is that the company, Zhixiang Jintai, has received acceptance for its new drug application for GR2001 injection, which is currently in the review queue, but did not apply for priority review during the listing application process [2][3] - The GR2001 injection is recognized as a breakthrough therapy, indicating its potential significance in treatment [2] - The new drug application was officially accepted in May 2025, suggesting a timeline for potential market entry [2]